gryptr,,2019-02-14 13:42:00,0.579,TROV Whats the status regarding under a buck delisting
Oxyur,False,2019-02-14 13:11:00,0.578,TROV Good News and Down
Oxyur,,2019-02-14 12:31:00,0.58,TROV
nickjun,,2019-02-14 11:44:00,0.5688,TROV whatever news comes out doesnt matter this sht jnk stock not moving significantly When I will see my average price 8 Screwed up
risenhoover,,2019-02-14 11:28:00,0.5909,Also if you are new to TROV heres some background for you httpsfinteliobtrovtrovageneanalysisandresearchreport17672
risenhoover,,2019-02-14 11:28:00,0.5909,TROV TrovaGene files form 8K httpsfinteliosustrov
je_mange_des_patates,True,2019-02-14 11:09:00,0.613,TROV nickjun u ll cover ur money Be patient Stop to be
stockcloud,True,2019-02-14 11:08:00,0.613,MYSZ RTTR CEI TROV Potential Reversal breakout VolumeVolatility Watch
cctranscripts,,2019-02-14 11:06:00,0.613,Trovagene Presents Update On Phase 2 Study Of Onvansertib In Combination With Zytiga In Patient conferencecalltranscriptso TROV
nickjun,False,2019-02-14 10:57:00,0.6089,TROV whatever news release doesdoesnt matter this sht jnk stock not moving when it will cross 1 28
je_mange_des_patates,True,2019-02-14 10:57:00,0.6089,TROV financeyahoocomnewstrov squeeze soon like SOLO or MBOT
Last10K,,2019-02-14 10:48:00,0.6026,TROV just filed a Financial Exhibit last10kcomsecfilingstrov
frenchfrog,,2019-02-14 10:41:00,0.6053,TROV We are pleased with the progress we are making in our Phase 2 mCRPC trial and to having our lead investigator Dr David Einstein
je_mange_des_patates,,2019-02-14 10:40:00,0.6152,financeyahoocomnewstrov TROV SOLO
frenchfrog,True,2019-02-14 10:40:00,0.6152,TROV Safety leadin completed no overlapping toxicities combination is safe and well tolerated
Haribobull,,2019-02-14 10:37:00,0.6323,TROV 066 wow
DangerDolan,True,2019-02-14 10:34:00,0.6162,TROV lets go
Volseeker,True,2019-02-14 10:33:00,0.5991,TROV
Rampart1,,2019-02-14 10:31:00,0.56,TROV Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCOGU Conference
